[Combined manifestations of natural foci in the territory of the Vologda province]

Autor: I V, Filonenko, N A, Rybakova, G G, Kuznetsov, N A, Evsiukova, L B, Launer

Publikováno v: Parazitologiia. 36(1)

Based on epizootological and epidemiological investigations in the Vologda province since 1958 till 2000, the combined territorial and temporal manifestations of natural foci of diseases was revealed. A natural focus occupies a complex of biotopes, a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::916d4656a7ac715c04c617f52723843f
https://pubmed.ncbi.nlm.nih.gov/11962199

The mechanism of growth of the carbonitrided case at a temperature above the eutectoid for the Fe?N system

Autor: G. G. Kuznetsov, E. I. Popova, E. L. Gyulikhandanov

Publikováno v: Metal Science and Heat Treatment. 26:288-292

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::33fdc452089ccbc052e507b0a23c6539
https://doi.org/10.1007/bf00699337

[Splenic abscess following suture of a perforated duodenal ulcer]

Autor: M I, Lupinskiĭ, G G, Kuznetsov

Publikováno v: Khirurgiia. (3)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::ff6fcb4d68401f42ff5e4be75d5dc800
https://pubmed.ncbi.nlm.nih.gov/978932

[Epizootiological characteristics of tularemia in the northwestern USSR]

Autor: Iu G, Liutov, V A, Shibalov, G V, Bogoiavlenskiĭ, G G, Kuznetsov

Publikováno v: Trudy Instituta imeni Pastera. 60

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::1c3cc439c9bf4c614399632570cae11f
https://pubmed.ncbi.nlm.nih.gov/6230766

Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states.

Autor: Yoshida T; Discovery Biology, Oncology Product Creation Unit, Eisai Co., Ltd, Tsukuba, Ibaraki 300-2635, Japan., Ozawa Y; Discovery Biology, Oncology Product Creation Unit, Eisai Co., Ltd, Tsukuba, Ibaraki 300-2635, Japan., Kimura T; Biomarkers and Personalized Medicine, Core Function Unit, Eisai Co., Ltd, Tsukuba, Ibaraki 300-2635, Japan., Sato Y; Biomarkers and Personalized Medicine, Core Function Unit, Eisai Co., Ltd, Tsukuba, Ibaraki 300-2635, Japan., Kuznetsov G; Biomarkers and Personalized Medicine, Core Function Unit, Eisai Inc., Andover, MA 01810, USA., Xu S; Biomarkers and Personalized Medicine, Core Function Unit, Eisai Inc., Andover, MA 01810, USA., Uesugi M; Biomarkers and Personalized Medicine, Core Function Unit, Eisai Co., Ltd, Tsukuba, Ibaraki 300-2635, Japan., Agoulnik S; Biomarkers and Personalized Medicine, Core Function Unit, Eisai Inc., Andover, MA 01810, USA., Taylor N; Biomarkers and Personalized Medicine, Core Function Unit, Eisai Inc., Andover, MA 01810, USA., Funahashi Y; Biomarkers and Personalized Medicine, Core Function Unit, Eisai Inc., Andover, MA 01810, USA., Matsui J; Discovery Biology, Oncology Product Creation Unit, Eisai Co., Ltd, Tsukuba, Ibaraki 300-2635, Japan.

Publikováno v: British journal of cancer [Br J Cancer] 2014 Mar 18; Vol. 110 (6), pp. 1497-505. Date of Electronic Publication: 2014 Feb 25.